Reshoring Debate Continues As COVID-19 Drives New Wave Of US Drug Shortages
As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.
You may also be interested in...
As agency prepares guidance on CARES Act requirement for risk management plans to help prevent shortages of critical medicines, industry raised concerns that a broad interpretation of the “life-saving drugs” term used in the legislation could make compliance challenging.
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.